MoneyWorks4Me

Sandu Pharmaceuticals informs about press release

18 Oct 2025 Evaluate
Sandu Pharmaceuticals has enclosed copy of Newspaper Advertisement published in the 'Navprabha' (English) and `Navprabha' (Marathi) newspapers, dated 18th October 2025 for Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares pursuant to SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97, dated July 02, 2025 and Launch of ‘Saksham Niveshak’ Campaign - Action Required for Unclaimed Dividends and KYC Updates. 

The above information is a part of company’s filings submitted to BSE.



Sandu Pharmaceutical Share Price

38.00 0.00 (0.00%)
19-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1898.00
Dr. Reddys Labs. 1171.00
Cipla 1416.00
Lupin 2220.00
Zydus Lifesciences 1105.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: